1-20 of 72
Danielle M Brander
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Adam S Kittai, Ying Huang, Sarah Miller, John N. Allan, Seema A Bhat, David A. Bond, Danielle M Brander, John C. Byrd, Julio C Chavez, Elise A. Chong, Matthew S Davids, Alexey Danilov, Wei Ding, Mark R Dowling, Kaitlyn M. Dvorak-Kornaus, Hannah Freedman, Paul J Hampel, Carrie I Ho, Steven R Hwang, Prioty Islam, Nitin Jain, Matthew Matasar, Cecelia Miller, Erin M Parry, Kari G. Rabe, Manoj Rai, Phil Raess, Lindsey E. Roeker, Joanna M. Rhodes, Kerry A Rogers, Aditi Saha, Jake Schade, Hamish S Scott, Mazyar Shadman, Geoffrey P. Shouse, Alan Skarbnik, Stephen E Spurgeon, Deborah M. Stephens, Meghan C. Thompson, Philip A. Thompson, Yucai Wang, William G. Wierda, Max Yano, Omer Zulfa, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 497.
https://doi.org/10.1182/blood-2023-182114
Published: 2023
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Jennifer A. Woyach, Deborah M. Stephens, Danielle M Brander, Adam S Kittai, Boyu Hu, Andrea Sitlinger, Emily K Curran, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, John C. Byrd
Journal: Blood
Blood (2023) 142 (Supplement 1): 328.
https://doi.org/10.1182/blood-2023-186432
Published: 2023
Journal Articles

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Tanya Siddiqi, David G Maloney, Saad S. Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San-San Ou, Neha Rane, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 330.
https://doi.org/10.1182/blood-2023-179529
Published: 2023
Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens
Journal: Blood
Blood (2021) 138 (Supplement 1): 392.
https://doi.org/10.1182/blood-2021-148672
Published: 2021
Journal Articles

SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. Tam, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepluch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen
Journal: Blood
Blood (2021) 138 (Supplement 1): 396.
https://doi.org/10.1182/blood-2021-148457
Published: 2021
Journal Articles

Novel Prognostic Markers in Previously Treated Chronic Lymphocytic Leukemia

Cindy M Pabon, Danielle M. Brander, Tiffany Stewart, J. Brice Weinberg
Journal: Blood
Blood (2021) 138 (Supplement 1): 4688.
https://doi.org/10.1182/blood-2021-152596
Published: 2021
Journal Articles

Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902)

Deborah M. Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael Fisch, Alexey V. Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steven Coutre, Susan M. O'Brien, Harry P. Erba
Journal: Blood
Blood (2021) 138 (Supplement 1): 2630.
https://doi.org/10.1182/blood-2021-144780
Published: 2021
Journal Articles

Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry

Max J. Gordon, Andy Kaempf, Emelie Rotbain, Andrea Sitlinger, Geoffrey Shouse, Matthew Mei, Danielle M. Brander, Tareq Salous, Brian T. Hill, Michael Choi, Jonathon B. Cohen, Deborah M. Stephens, Dan O. Persky, Krish Patel, Mazyar Shadman, Byung Park, Carsten Utoft Niemann, Alexey V. Danilov
Journal: Blood
Blood (2021) 138 (Supplement 1): 2637.
https://doi.org/10.1182/blood-2021-148253
Published: 2021
Journal Articles

Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax

Meghan C. Thompson, Lindsey E. Roeker, Catherine C. Coombs, Jeffrey L. Jensen, Manali Kamdar, Alan Skarbnik, John M. Pagel, Neil Bailey, Jeffrey J. Pu, Ryan Jacobs, Brian T. Hill, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Kristen E. Battiato, Celina J. Komari, Guilherme Sacchi De Camargo Correia, Julia H. Aronson, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Paul M. Barr, Craig A. Portell, Nicole Lamanna, Javier Pinilla-Ibarz, Andrew D. Zelenetz, Stephen J Schuster, John N. Allan, Toby A. Eyre, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 2628.
https://doi.org/10.1182/blood-2021-150751
Published: 2021
Journal Articles

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML

Marina Konopleva, Danielle M. Brander, Krish Patel, Catherine S. Diefenbach, Yesid Alvarado, Olga Frankfurt, Monzr M. Al Malki, Alexey V. Danilov, Sameem Abedin, Kebede H. Begna, Avyakta Kallam, Richard G. Ghalie, Matthew S. Davids
Journal: Blood
Blood (2021) 138 (Supplement 1): 3423.
https://doi.org/10.1182/blood-2021-146079
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia

Matthew S. Davids, Danielle M. Brander, Svitlana Tyekucheva, Chinheng Chen, James Kaminski, Josie Montegaard, Alvaro J. Alencar, Leyla Shune, Mohammad Omaira, Caron Jacobson, Philippe Armand, Samuel Y. Ng, Jennifer L. Crombie, Ann S. LaCasce, Jon E. Arnason, Ephraim Hochberg, Ronald W. Takvorian, Jeremy S. Abramson, David C. Fisher, Jennifer R Brown
Journal: Blood
Blood (2021) 138 (Supplement 1): 640.
https://doi.org/10.1182/blood-2021-146624
Published: 2021
Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry Rogers, Sameer A. Parikh, Steven Coutre, Gerard Lozanski, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, James S. Blachly, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Jennifer R Brown, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd
Journal: Blood
Blood (2021) 138 (Supplement 1): 639.
https://doi.org/10.1182/blood-2021-153146
Published: 2021
Journal Articles

Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy

Clinical Trials & Observations
Shuo Ma, John F. Seymour, Danielle M. Brander, Thomas J. Kipps, Michael Y. Choi, Mary Ann Anderson, Kathryn Humphrey, Abdullah Al Masud, John Pesko, Ruby Nandam, Ahmed Hamed Salem, Brenda Chyla, Jennifer Arzt, Amanda Jacobson, Su Young Kim, Andrew W. Roberts
Journal: Blood
Blood (2021) 138 (10): 836–846.
https://doi.org/10.1182/blood.2020009578
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Clinical Trials & Observations
Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Cheson, Paul M. Barr, Suman Kambhampati, Frederick Lansigan, Jeffrey J. Pu, Alan P. Skarbnik, Lindsey Roeker, Gustavo A. Fonseca, Andrea Sitlinger, Issam S. Hamadeh, Colleen Dorsey, Nicole LaRatta, Hanna Weissbrot, Eline T. Luning Prak, Patricia Tsao, Dana Paskalis, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Jakub Svoboda, Danielle M. Brander
Journal: Blood
Blood (2021) 137 (20): 2817–2826.
https://doi.org/10.1182/blood.2020007376
Published: 2021
Includes: Supplemental data
Journal Articles

Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families

CME Clinical Trials & Observations
Susan L. Slager, Mark C. Lanasa, Gerald E. Marti, Sara J. Achenbach, Nicola J. Camp, Fatima Abbasi, Neil E. Kay, Celine M. Vachon, James R. Cerhan, James B. Johnston, Timothy G. Call, Kari G. Rabe, Geffen Kleinstern, Nicholas J. Boddicker, Aaron D. Norman, Sameer A. Parikh, Jose F. Leis, Versha Banerji, Danielle M. Brander, Martha Glenn, Alessandra Ferrajoli, Karen Curtin, Esteban Braggio, Tait D. Shanafelt, Mary L. McMaster, J. Brice Weinberg, Curtis A. Hanson, Neil E. Caporaso
Journal: Blood
Blood (2021) 137 (15): 2046–2056.
https://doi.org/10.1182/blood.2020006322
Published: 2021
Includes: Supplemental data
Journal Articles

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Dandan Zheng, Kavita Sail, PhD, Lindsey E Roeker, MD, Beenish S Manzoor, PhD, Hande H. Tuncer, MD, John N. Allan, MD, Chaitra S. Ujjani, MD, Paul M. Barr, MD, Jennifer R. Brown, MD PhD, Toby A. Eyre, Alan Skarbnik, MD, Rajat Bannerji, MDPhD, Barbara Eichhorst, MD, Danielle M. Brander, MD, Simon Sharmokh, MPH, PharmD, Daniel Dingfeng Jiang, MD PhD, German Pena, MD, Rajesh Kamalakar, MS, Nnadozie Emechebe, MPH, Irina Pivneva, Rebecca Burne, Annie Guerin, MSc, Matthew S. Davids, MD, Anthony Mato, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–22.
https://doi.org/10.1182/blood-2020-134676
Published: 2020
Journal Articles

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, MD, Stephen J. Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Shalin K. Kothari, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Allison C. Rosenthal, D.O., Jose F. Leis, MD PhD, Han W. Tun, MD, Kaitlin Kennard, RN, BSN, Allison R. Nelson, RN, Victoria Falco, BSN, Celina J. Komari, BS, Amber B. Koehler, PA-C, MS, Rachel Stowe, RN, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Tim McKinlay, Lindsey E Roeker, MD, Meghan C. Thompson, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-138896
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020